Elmiron® was approved by the FDA for sale in 1996 and it remains the only oral drug approved for consumers with Interstitial Cystitis. It is not available as a generic in the United States, although a generic form does exist outside of the US.
The Emory Eye Center in Atlanta, Georgia observed a new eye disease between 2015 and 2018 in which the pigment cells within the retina of the eye changed color with patients having serious vision damage similar to that with patients having age-related macular degeneration. The Emory researchers found that each of the patients with this condition were taking Elmiron® for Interstitial Cystitis over a lengthy period of time.
The Emory research prompted Kaiser Permanente to examine their patient database and found they had 91 patients, who had been taking Elmiron® for a minimum of 5 years. Of these women, 24% had eye damage, which increased in severity as the quantity of Elmiron® increased over time.
The first National Multicenter Study by the Emory Eye Center (November 2019) which reviewed data from a large medical claims database between 2002 and 2016 revealed that patients having 7 years of Elmiron® use had significantly increased odds of experiencing atypical maculopathy and age-related macular degeneration.
To date, despite these studies and the belief that the correlation between vision loss and use of Elmiron® may have been known previous to the above studies, there are NO warnings on the Elmiron® prescription use label relating to vision loss as a side effect of this drug.
Ophthalmologists have special optical examinations and tests to help diagnose this atypical maculopathy, if macular degeneration is suspected after chronic use of Elmiron®.
If you have been taking the medication Elmiron® and are suffering from any of the macular degeneration symptoms listed above, you may be entitled to compensation. Click, Chat or call 1800LAW1010 24/7 for a free case evaluation.